User profiles for Dongsheng Tu
 | Dongsheng TuProfessor of Biostatistics, Queen's University at Kingston, Canada Verified email at ctg.queensu.ca Cited by 50103 |
[BOOK][B] The jackknife and bootstrap
… Dongsheng Tu … Jun Shao Dongsheng Tu … Dongsheng Tu Institute of System Science
Academia Sinica Beijing, 100080 People's Republic of China …
Academia Sinica Beijing, 100080 People's Republic of China …
[HTML][HTML] Erlotinib in previously treated non–small-cell lung cancer
…, M van Kooten, M Dediu, B Findlay, D Tu… - New England journal …, 2005 - Mass Medical Soc
Background We conducted a randomized, placebo-controlled, double-blind trial to determine
whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non–…
whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non–…
[HTML][HTML] K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
…, DJ Jonker, CJ O'Callaghan, D Tu… - … England Journal of …, 2008 - Mass Medical Soc
Background Treatment with cetuximab, a monoclonal antibody directed against the epidermal
growth factor receptor, improves overall and progression-free survival and preserves the …
growth factor receptor, improves overall and progression-free survival and preserves the …
[HTML][HTML] Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
…, R Gryfe, LE Shepherd, D Tu… - … England Journal of …, 2003 - Mass Medical Soc
Background Colon cancers with high-frequency microsatellite instability have clinical and
pathological features that distinguish them from microsatellite-stable tumors. We investigated …
pathological features that distinguish them from microsatellite-stable tumors. We investigated …
[HTML][HTML] A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
…, MJ Piccart, M Castiglione, D Tu… - … England Journal of …, 2003 - Mass Medical Soc
Background In hormone-dependent breast cancer, five years of postoperative tamoxifen
therapy — but not tamoxifen therapy of longer duration — prolongs disease-free and overall …
therapy — but not tamoxifen therapy of longer duration — prolongs disease-free and overall …
[HTML][HTML] Cetuximab for the treatment of colorectal cancer
Background Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth
factor receptor (EGFR), has activity against colorectal cancers that express EGFR. Methods …
factor receptor (EGFR), has activity against colorectal cancers that express EGFR. Methods …
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17
…, MJ Piccart, M Castiglione, D Tu… - Journal of the …, 2005 - academic.oup.com
Background: Most recurrences in women with breast cancer receiving 5 years of adjuvant
tamoxifen occur after 5 years. The MA.17 trial, which was designed to determine whether …
tamoxifen occur after 5 years. The MA.17 trial, which was designed to determine whether …
[HTML][HTML] Morphine, gabapentin, or their combination for neuropathic pain
Background The available drugs to treat neuropathic pain have incomplete efficacy and
dose-limiting adverse effects. We compared the efficacy of a combination of gabapentin and …
dose-limiting adverse effects. We compared the efficacy of a combination of gabapentin and …
[HTML][HTML] Exemestane for breast-cancer prevention in postmenopausal women
…, E Maunsell, P Farmer, KA Gelmon, D Tu… - … England Journal of …, 2011 - Mass Medical Soc
Background Tamoxifen and raloxifene have limited patient acceptance for primary prevention
of breast cancer. Aromatase inhibitors prevent more contralateral breast cancers and …
of breast cancer. Aromatase inhibitors prevent more contralateral breast cancers and …
Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
Context Patients with metastatic colorectal cancer who have KRAS codon 12– or KRAS codon
13–mutated tumors are presently excluded from treatment with the anti–epidermal growth …
13–mutated tumors are presently excluded from treatment with the anti–epidermal growth …